31 research outputs found
Supplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S1: Demographics by therapy</p
Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes</p
Supplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S4: Lymphocyte infiltration</p
Supplementary Table S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S2: Median changes in percentage of nelipepimut (NPS)-specific cytotoxic lymphocytes (CTL)</p
Supplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S1: Demographics by therapy</p
Supplementary Table S5 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S5: HER2 expression in biopsy and resection specimens</p
Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S3: Pathologic characteristics</p
Supplementary Table S5 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S5: HER2 expression in biopsy and resection specimens</p
Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Table S3: Pathologic characteristics</p
Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>
No full textSupplementary Fig. S1: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving NeuVax with corresponding HER2 changes</p
